“Neither Novo Nordisk nor FDA can confirm the contents ... but analysis found that “needles from the samples are counterfeit” and cannot be guaranteed to be sterile, meaning that use of ...

Novo Nordisk (NVO) is reportedly set to meet with ... significant barriers to demonstrating biosimilarity without a sample to reference,” the senators added in their statement.

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

Ozempic maker Novo Nordisk NOVO.B-0.94%decrease; red down pointing triangle pushed out its chief executive after losing ground in the anti-obesity drug market, which has caused a steep stock-price ...

Novo Nordisk's sales have been growing fast thanks to GLP-1 medicines like Ozempic for diabetes and Wegovy for weight management. In 2024, revenue increased by 25% year over year to 290 billion ...

Novo Nordisk NOVO.B-2.41%decrease; red down pointing triangle shares rallied Wednesday as investors breathed a sigh of relief after first-quarter earnings beat expectations and the company’s ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Novo Nordisk (NYSE: NVO) stock tumbled 3.9% through 10:45 a.m. ET this morning after the manufacturer of GLP-1 weight loss drugs announced its CEO, Lars Fruergaard Jørgensen, will step down from ...

The federal agency and Novo Nordisk, the Danish pharmaceutical giant that makes Ozempic, said this week that they had learned about "several hundred units" of the drug that made it onto the market ...

By Rebecca Robbins Novo Nordisk will replace its chief executive, Lars Fruergaard Jorgensen, the company announced Friday, citing a sharp decline in its stock price that stemmed from increased ...

The agreements cap patients’ monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs ...

Novo Nordisk will invest $4.1 billion to develop a new manufacturing facility in the U.S., which will be used to boost production for the company’s weight loss and diabetes drugs Wegovy and ...